Cover Image
市場調查報告書

乾癬治療藥的全球市場:藥物分子、投藥途徑、各作用機制的未來展望

Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 451123
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
乾癬治療藥的全球市場:藥物分子、投藥途徑、各作用機制的未來展望 Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022
出版日期: 2017年02月13日 內容資訊: 英文 70 Pages
簡介

本報告提供全球乾癬治療藥的市場相關分析,疾病概要和主要的治療方法,推動及阻礙市場要素,今後的市場趨勢預測,各藥物分子、各投藥途徑、各作用機制、各地區的詳細趨勢,最新的市場形勢、課題與未來的方向性,主要企業簡介等調查。

第1章 分析師的見解

第2章 分析方法

第3章 乾癬:概要

第4章 市場動態

  • 推動因素
  • 課題
  • 機會

第5章 全球乾癬治療藥市場未來展望

第6章 市場區隔:各藥物分子類型

  • 生技藥品
  • 小分子/化學藥物

第7章 市場區隔:各投藥途徑

  • 全身性
  • 局部給藥

第8章 市場區隔:各作用機制

  • TNF (腫瘤壞死因子) 抑制劑
  • 白細胞介素抑制劑
  • 其他

第9章 市場區隔:各地區

  • 北美
  • 歐洲
  • 亞太地區

第10章 市場趨勢和動靜

  • 白細胞介素抑制劑的市場促進
  • TNF-α抑制劑:乾癬治療用

第11章 企業合併、收購 (M&A) 及產業聯盟

第12章 開發平台分析

第13章 波特的五力分析

第14章 主要企業

目錄

Psoriasis is a chronic, non-communicable, painful, disfiguring and disabling disease. This disease causes rapid build-up of skin cells. This disease can occur at any age, and is most common in the age group of 50-69 years. According to World Health Organization, the prevalence of psoriasis in different countries ranges between 0.09% and 11.4%. Treatment of this disease is based on controlling of its symptoms. Topical and systemic therapy drugs are used in combination, in order to combat this disease.

As per RNCOS report “Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022” , the global psoriasis drugs market is anticipated to witness a high growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market.

The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe.

Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global psoriasis drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global psoriasis drugs industry. The pipeline of psoriasis drugs have also been mentioned in the report.

The last section of the report discusses about the prominent players in global psoriasis drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global psoriasis drugs market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Psoriasis: An Overview

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Rising Prevalence of Psoriasis
    • 4.1.2. Increasing Awareness
    • 4.1.3. Growing Geriatric Population
    • 4.1.4. Rising Healthcare Expenditure
  • 4.2. Challenges
    • 4.2.1. Patent Cliff of Blockbuster Drugs
    • 4.2.2. High Cost
  • 4.3. Opportunities
    • 4.3.1. Biologic Drugs Flaring Up Psoriasis Drugs Market
    • 4.3.2. Incessant Launch of Novel Products

5. Global Psoriasis Drugs Market Outlook 2022

6. Market Segmentation by Type of Drug Molecule

  • 6.1. Biologic Drugs
  • 6.2. Small Molecule/Chemical Drugs

7. Market Segmentation by Route of Administration

  • 7.1. Systemic
  • 7.2. Topical

8. Market Segmentation by Mechanism of Action

  • 8.1. TNF Inhibitors
  • 8.2. Interleukin Blockers
  • 8.3. Others

9. Market Segmentation by Geography

  • 9.1. North America
  • 9.2. Europe
  • 9.3. Asia-Pacific

10. Trends & Developments

  • 10.1. Interleukin Inhibitors Driving Psoriasis Drugs Market
  • 10.2. TNF-alpha Blockers for the Treatment of Psoriasis

11. Mergers, Acquisitions & Collaborations

12. Pipeline Analysis

13. Porter's Five Forces Analysis

14. Key Players

  • 14.1. AbbVie Inc.
  • 14.2. Biocon
  • 14.3. Pfizer Inc.
  • 14.4. Novartis
  • 14.5. Eli Lilly and Company.
  • 14.6. Celltrion Inc.
  • 14.7. Celgene Corporation
  • 14.8. Johnson & Johnson
  • 14.9. Dr.Reddy's Laboratories
  • 14.10. Amgen Inc.

List of Figures:

  • Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050
  • Figure 5-1: Global - Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 6-1: Global - Psoriasis Drugs Market by Type of Drug Molecule (%), 2016
  • Figure 6-2: Global - Biologic Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 6-3: Global - Small Molecule/Chemical Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 7-1: Global - Psoriasis Drugs Market by Route of Administration (%), 2016
  • Figure 7-2: Global - Systemic Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 7-3: Global - Topical Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 8-1: Global - Psoriasis Drugs Market by Mechanism of Action (%), 2016
  • Figure 8-2: Global - TNF Inhibitor Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 8-3: Global - Interleukin Blocker Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 8-4: Global - Other Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 9-1: Global - Psoriasis Drugs Market by Geography (%), 2016
  • Figure 9-2: North America - Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 9-3: Europe - Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 9-4: Asia-Pacific - Psoriasis Drugs Market (Billion US$), 2016 & 2022
  • Figure 14-1: AbbVie Inc. - Revenue by Geography (%), 2015
  • Figure 14-2: Biocon - Revenue by Business Segments (%), FY 2016
  • Figure 14-3: Biocon - Revenue by Geography (%), FY 2016
  • Figure 14-4: Pfizer Inc. - Revenue by Business Segments (%), 2015
  • Figure 14-5: Pfizer Inc. - Revenue by Geography (%), 2015
  • Figure 14-6: Novartis - Net Sales by Business Segments (%), 2016
  • Figure 14-7: Novartis - Net Sales by Geography (%), 2016
  • Figure 14-8: Eli Lilly and Company - Revenue by Business Segments (%), 2015
  • Figure 14-9: Eli Lilly and Company - Revenue by Geography (%), 2015
  • Figure 14-10: Celltrion Inc. - Revenue by Business Segments (%), 2015
  • Figure 14-11: Celgene Corporation - Revenue by Products (%), 2015
  • Figure 14-12: Celgene Corporation - Revenue by Geography (%), 2015
  • Figure 14-13: Johnson & Johnson - Revenue by Business Segments (%), 2015
  • Figure 14-14: Johnson & Johnson - Revenue by Geography (%), 2015
  • Figure 14-15: Dr. Reddy's - Revenue by Business Segments (%), 2016
  • Figure 14-16: Dr. Reddy's - Revenue by Geography (%), 2016
  • Figure 14-17: Amgen Inc. - Revenue by Geography (%), 2015

List of Tables:

  • Table 11-1: Mergers, Acquisitions & Collaborations in Psoriasis Drugs Market (2014-2016)
  • Table 12-1: Global - Psoriasis Drugs Pipeline Analysis
  • Table 14-1: AbbVie Inc. - Financials (Million US$), 2013, 2014 & 2015
  • Table 14-2: Biocon - Financials (Million US$), FY 2014, FY 2015 & FY 2016
  • Table 14-3: Pfizer Inc. - Financials (Million US$), 2013, 2014 & 2015
  • Table 14-4: Novartis - Financials (Billion US$), 2014, 2015 & 2016
  • Table 14-5: Eli Lilly and Company - Financials (Billion US$), 2013, 2014 & 2015
  • Table 14-6: Celltrion Inc. - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 14-7: Celgene Corporation - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 14-8: Johnson & Johnson - Total Sales (Billion US$), 2013, 2014 & 2015
  • Table 14-9: Dr. Reddy's - Total Sales (Billion US$), 2014, 2015 & 2016
  • Table 14-10: Amgen Inc. - Revenue, (Billion US$), 2013, 2014 & 2015
Back to Top